Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.56 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912104 | 0.90 | LRRK2 (0.71) | LRRK2PTK2EGFRMKNK2MAP3K9 | |
| SCHEMBL1911944 | 0.90 | LRRK2 (0.74) | LRRK2PTK2EGFRMKNK2MAP3K9 | |
| SCHEMBL14981294 | 0.89 | PTK2 (0.72) | LRRK2PTK2EGFRINSRIGF1R | |
| SCHEMBL14981326 | 0.83 | LRRK2 (0.79) | LRRK2MKNK2MAP3K9 | |
| SCHEMBL9279968 | 0.83 | LRRK2 (1.00) | LRRK2MKNK2MAP3K9JAK2 | |
| SCHEMBL12729763 | 0.82 | PTK2 (0.61) | LRRK2PTK2EGFRMKNK2INSR | |
| SCHEMBL1911966 | 0.82 | ALK (0.62) | LRRK2PTK2EGFRMKNK2MAP3K9 | |
| SCHEMBL12780545 | 0.81 | LRRK2 (0.66) | LRRK2MKNK2MAP3K9JAK2 | |
| SCHEMBL12780618 | 0.79 | MAPK9 (0.61) | LRRK2PTK2EGFRMKNK2INSR | |
| SCHEMBL12728765 | 0.77 | ALK (0.60) | LRRK2PTK2EGFRMKNK2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | LRRK2 3211/4885PTK2 3952/4885EGFR 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.